פראג'קט 200 וטרינרי
abic veterinary products ltd - ferrous as dextran - תמיסה להזרקה - ferrous as dextran 200 mg/ml
קרדישור בטעם וטרינרי 1.25 מג
vetmarket ltd, israel - pimobendan - טבליה - pimobendan 1.25 mg
קרדישור בטעם וטרינרי 10 מג
vetmarket ltd, israel - pimobendan - טבליה - pimobendan 10 mg
קרדישור בטעם וטרינרי 2.5 מג
vetmarket ltd, israel - pimobendan - טבליה - pimobendan 2.5 mg
קרדישור בטעם וטרינרי 5 מג
vetmarket ltd, israel - pimobendan - טבליה - pimobendan 5 mg
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii
וילאט 500
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii
סנדאימון תמיסה מרוכזת לאינפוזיה
novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.
רבלימיד 5 מ"ג
neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.